Development And Characterization Of Liposomes Containing Relugolix
Main Article Content
Abstract
Research study investigates the formulation and characterization of Relugolix-loaded liposomes using a systematic approach involving various analytical methods. Relugolix, an BCS IV anticancer, was assessed for its physical properties, melting point, and solubility across multiple solvents, revealing optimal solubility in ethanol. UV spectroscopy established the absorption maxima at 247 nm, facilitating the development of a calibration curve in phosphate buffer pH 6.8. Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) provided insights into the drug's chemical interactions and thermal behavior, respectively. Liposomes were prepared using the solvent evaporation method, and their formulation was optimized through a Box-Behnken design focusing on soya lecithin, cholesterol, and rotational speed. The optimized formulation (F8) exhibited a drug content of 97.56% and an entrapment efficiency of 95.78%, alongside promising in vitro drug diffusion profiles reaching 96.87% over 12 hours. Stability studies demonstrated that these parameters remained consistent over one month. Overall, this research highlights the potential of Relugolix-loaded liposomes for effective drug delivery, paving the way for future in vivo efficacy studies.
Article Details
References
Smith MR, et al. Relugolix for the treatment of prostate cancer: a review. Cancer Treatment Reviews. 2020;87:102042. DOI: 10.1016/j.ctrv.2020.102042.
Amidon GL, et al. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug release and in vivo bioavailability. Pharmaceutical Research. 1995;12(3):413-420. DOI: 10.1023/A:1016212802808.
Kauffman AS, et al. GnRH antagonists: a new strategy for the treatment of prostate cancer. Nature Reviews Urology. 2015;12(7):387-394. DOI: 10.1038/nrurol.2015.67.
Jameel F, Amiji M. Formulation strategies for improving the solubility of BCS class IV drugs. Current Drug Metabolism. 2015;16(7):625-639. DOI: 10.2174/1389201016666150716151309.
Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews. 2013;65(1):36-48. DOI: 10.1016/j.addr.2012.09.037.
Kallinteri P, et al. Liposomes: a review of their applications in cancer therapy. Pharmaceutics. 2015;7(4):352-377. DOI: 10.3390/pharmaceutics7040352.
Raut SK, et al. Liposomes: a review on therapeutic applications. Research Journal of Pharmacy and Technology. 2016;9(6):689-698. DOI: 10.5958/0974-360X.2016.00132.5.
Liu Y, et al. Characterization of drug delivery systems. Journal of Controlled Release. 2016;240:224-236. DOI: 10.1016/j.jconrel.2016.11.017.
Vippagunta SK, et al. Solubility and dissolution rate enhancement of poorly soluble drugs: a review. Drug Development and Industrial Pharmacy. 2007;33(7):733-744. DOI: 10.1080/03639040701489312.
Choudhary M, et al. Characterization of drug-polymer interactions using FTIR and DSC. Asian Journal of Pharmaceutical Sciences. 2016;11(5):701-708. DOI: 10.1016/j.ajps.2016.06.002.
Nakanishi K, et al. Application of X-ray diffraction to the characterization of pharmaceuticals. Pharmaceutical Science & Technology Today. 2006;9(4):154-160. DOI: 10.1016/j.pst.2006.02.001.
Box GE, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics. 1960;2(4):455-475. DOI: 10.1080/00401706.1960.10489910.
Pacheco A, et al. Influence of lipid composition on drug release from liposomes. International Journal of Pharmaceutics. 2013;458(1):172-178. DOI: 10.1016/j.ijpharm.2013.10.013.
Mura S, et al. Stability of liposomes: effects of formulation and processing. Journal of Drug Delivery Science and Technology. 2013;23(2):93-104. DOI: 10.1016/S1773-2247(13)50015-1.
Zhang Y, et al. Advanced nanoparticle characterization techniques for drug delivery applications. Molecular Pharmaceutics. 2017;14(7):2076-2088. DOI: 10.1021/acs.molpharmaceut.6b01136.
Bouchard J, et al. In vitro diffusion techniques: assessing the release of drugs from liposomal formulations. European Journal of Pharmaceutics and Biopharmaceutics. 2016;109:41-48. DOI: 10.1016/j.ejpb.2016.08.005.
Raghavan K, et al. Use of scanning electron microscopy (SEM) and transmission electron microscopy (TEM) in the characterization of drug delivery systems. Journal of Drug Delivery Science and Technology. 2018;43:119-128. DOI: 10.1016/j.jddst.2017.10.022.
Gao X, et al. Quality control of liposomal formulations: challenges and solutions. Journal of Pharmaceutical Sciences. 2016;105(9):2275-2285. DOI: 10.1016/j.xphs.2016.05.026.
Poncelet M, et al. In vitro drug release testing of liposomal formulations. European Journal of Pharmaceutics and Biopharmaceutics. 2014;88(2):285-290. DOI: 10.1016/j.ejpb.2014.03.016.
Karami Z, et al. Stability studies of liposomal formulations. International Journal of Pharmaceutics. 2016;514(1):19-32. DOI: 10.1016/j.ijpharm.2016.10.012.
De Paola D, et al. Characterization of liposomal drug delivery systems: particle size and zeta potential. Drug Development and Industrial Pharmacy. 2012;38(5):569-579. DOI: 10.3109/03639045.2011.588669.
Bansal AK, Singh K. Characterization of pharmaceuticals. Pharmaceutical Research. 2016;33(1):125-143. DOI: 10.1007/s11095-015-1796-8.
ICH. Q2 (R1) Validation of analytical procedures: text and methodology. International Conference on Harmonisation; 2005. Available from: ICH Guidelines.